Anatomic Stage IV Breast Cancer AJCC v8 Clinical Trials in New Haven, Connecticut

3 studies are recruiting for anatomic stage iv breast cancer ajcc v8 in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

   This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Locations

   30 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03606967 on ClinicalTrials.gov

2. Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

   This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treatin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut

   Locations

   59 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT07578116 on ClinicalTrials.gov

3. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

   This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut

   Locations

   723 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT03723928 on ClinicalTrials.gov